Race Oncology (ASX:RAC) has announced the appointment of experienced biotechnology executive Dr Megan Baldwin to its board as an independent non-executive director.

AusBiotech has formalised a new partnership with BioNSW, a rapidly growing not-for-profit organisation dedicated to harnessing the full potential of the New South Wales Life Sciences sector.

Australasian Biotechnology is AusBiotech’s official biannual journal, published in September and April. Written by the sector, for the sector highlighting topics such as technology development, manufacturing excellence, sustainability, and strategies to strengthen Australia’s end-to-end life sciences value chain.

Led by BioMelbourne Network, the new initiative brings together expertise from peak industry bodies and companies to create a voice and advocate on behalf of Victorian medtech manufacturers across the key issues impacting the sector. 

Clinical-stage company Immutep (ASX:IMM) has announced new findings published in Science Immunology that resolve how human lymphocyte activation gene 3 binds to its main ligand MHC Class II (MHC-II), also known as HLA Class II in humans.

PYC Therapeutics (ASX:PYC) has announced it plans to progress investigational drug candidate PYC-002 into human clinical trials for Phelan-McDermid Syndrome.

Scientists from RMIT University and the Doherty Institute have developed a new blood test that could screen cancer patients to help make their treatment safer and more effective.

Premier Jacinta Allan announced the plan focused on priority sectors, including advanced manufacturing, health technologies and medical research.

Immutep (ASX:IMM) has announced positive clinical results from Cohort B of the TACTI-003 (KEYNOTEC34) Phase 2b trial.

Clinical-stage biotechnology company FivepHusion has announced a commercial transaction with the University of Wollongong for an exclusive option over its ResectAssist Drug Delivery Platform.

An immunotherapy that targets out-of-control viral infections has saved the lives of dozens of critically ill immunocompromised Australians who received the treatment on compassionate grounds.

Neuren Pharmaceuticals (ASX: NEU) has announced that the sale of the Rare Pediatric Disease Priority Review Voucher by its partner Acadia Pharmaceuticals has been completed.

Paradigm Biopharmaceuticals (ASX:PAR) has announced that it has received firm commitments for a capital raising totalling $16 million through a placement of fully paid ordinary shares to sophisticated and institutional investors.

Recce Pharmaceuticals (ASX:RCE) has received approval from the Indonesian Drug and Food Regulatory Authority to initiate its registrational Phase 3 clinical trial, which will assess RECCE 327 as a topical gel for treating diabetic foot infections.

Queensland company NuNerve has announced promising early results in a Phase 1 patient cohort of eight people with MND and 20 healthy volunteers who were dosed with its lead compound NUN-004 for six months.

Cyclopharm (ASX:CYC) has announced the publication of the first US-based study highlighting the clinical utility and operational benefits of its proprietary Technegas technology.

Alterity Therapeutics (ASX:ATH) has announced that the last patient in its ATH434-201 Phase 2 trial in early-stage multiple system atrophy has completed the study.